

GenSight Biologics Announces Annual General Meeting to Take Place on May 19, 2026

Procedures for obtaining preparatory documents for the General Meeting are described below.

Paris, France, April 28, 2026, 8:30 pm CEST – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced that it will hold its Annual General Meeting on May 19, 2026, at 2:00 pm CEST at the Company's headquarters at 74 rue du Faubourg Saint-Antoine, 75012 Paris, France.

The General Meeting will also be webcast live for shareholders at the following link: <https://gensightbiologics.engagestream.euronext.com/2026-05-19-ag>.

The notice containing the agenda and draft resolutions was published in the French *BALO* on April 13, 2026. The notice confirming the time and place of the meeting will be published in the French *BALO* and in a legal gazette on May 4, 2026.

The preparatory documents for the General Meeting listed in Article R. 22-10-23 of the French Commercial Code are posted on the Company's website (www.gensight-biologics.com) in the Investors/Documentation section.

The preparatory documents for the General Meeting will also be made available to shareholders as of the convening of the meeting.

It is specified that the full text of the documents intended to be presented to the Meeting, in accordance in particular with Articles L. 225-115 and R. 225-83 of the Commercial Code, are made available at the Company's headquarters.

From the date of the convocation and until the fifth day inclusive before the meeting, any shareholder may ask the Company to send him the documents and information mentioned in Articles R. 225-81 and R. 225-83 of the Commercial Code, preferably by email to the following address: investor_relations@gensight-biologics.com. Bearer shareholders must justify this status by sending an account registration certificate.

Contacts

GenSight Biologics

Chief Financial Officer

Jan Eryk Umiastowski

jeumiasowski@gensight-biologics.com

About GenSight Biologics

GenSight Biologics S.A. is a clinical-stage biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. GenSight Biologics' pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. GenSight Biologics' lead product



candidate, GS010 (lenadogene nolparvovec) is in Phase III in Leber Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease that leads to irreversible blindness in teens and young adults. GS010 is currently in clinical development, has not to date been granted marketing authorization in France or any other jurisdiction, and is therefore not available commercially. Using its gene therapy-based approach, GenSight Biologics' product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery.